Meeting
2020 ASCO Virtual Scientific Program
Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): Secondary and final primary efficacy analyses.
Authors
Daniel V.T. Catenacci
University of Chicago Medical Center and Biological Sciences, Chicago, IL
Daniel V.T. Catenacci , Bryan Peterson , Leah Chase , Samantha Lomnicki , Anthony Serritella , Natalie Reizine , Chih-Yi Liao , Lindsay Alpert , Namrata Setia , John Hart , Uzma Siddiqui , Sunil Narula , Murtuza M. Rampurwala , Yuan Ji , Theodore Karrison , Blase N. Polite , Hedy L. Kindler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02213289
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4561)
DOI
10.1200/JCO.2020.38.15_suppl.4561
Abstract #
4561
Poster Bd #
169
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Personalized ANtibodies for GastroEsophageal Adenocarcinoma (PANGEA): Primary efficacy analysis of the phase II platform trial (NCT02213289).
First Author: Daniel V.T. Catenacci
Poster
2023 ASCO Annual Meeting
Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated biliary tract cancer.
First Author: Wen-Zhuo He
Poster
2018 Gastrointestinal Cancers Symposium
Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II precision medicine trial (NCT02213289).
First Author: Smita Suhas Joshi
Poster
2015 ASCO Annual Meeting
CD137 co-stimulation and blocking PD-1 enhances NK cell-mediated target cell lysis by CD30/CD16A TandAb AFM13.
First Author: Xing Zhao